06996.HK
Antengene Corporation Limited
HKSE · Healthcare · Biotechnology · CN
HKD 3.56
−0.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 642.5M | 105.3M | 92.0M | 67.3M | 160.1M |
| Cost of Revenue | 66.8M | 18.5M | 17.8M | 12.3M | 28.1M |
| Gross Profit | 575.7M | 86.8M | 74.2M | 55.0M | 132.0M |
| Operating Expenses | |||||
| R&D Expense | 416.0M | 169.1M | 258.9M | 405.7M | 488.5M |
| SG&A Expense | 287.6M | 156.6M | 180.0M | 340.8M | 522.4M |
| General & Admin Expense | 135.3M | 87.5M | 106.3M | 148.1M | 167.1M |
| Selling & Marketing Expense | 86.9M | 69.2M | 73.7M | 192.7M | 355.4M |
| Other Expenses | 777.1K | — | — | — | — |
| Total Operating Expenses | 704.4M | 325.7M | 438.9M | 746.5M | 1.0B |
| Cost and Expenses | 771.2M | 344.2M | 456.7M | 758.8M | 1.0B |
| Operating Income (EBIT) | (128.7M) | (238.9M) | (364.7M) | (691.5M) | (878.9M) |
| Non-Operating | |||||
| Interest Income | 27.4M | 10.8M | 32.7M | 38.8M | 28.2M |
| Interest Expense | 6.2M | 2.3M | 642.0K | 898.0K | 974.0K |
| Net Interest Income | 21.1M | 8.5M | 32.1M | 37.9M | 27.2M |
| Other Non-Op Income/Expense | (49.3M) | (219.0K) | 45.5M | 110.3M | 277.4M |
| Non-Operating Income (excl Interest) | — | — | — | (111.2M) | — |
| EBT (Pre-Tax Income) | (178.0M) | (239.1M) | (319.3M) | (581.2M) | (601.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (178.0M) | (239.1M) | (319.3M) | (581.2M) | (601.5M) |
| Earnings from Cont. Ops | (178.0M) | (239.1M) | (319.3M) | (581.2M) | (601.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (178.0M) | (239.1M) | (319.3M) | (581.2M) | (601.5M) |
| Per Share | |||||
| Basic EPS | (HK$0.28) | (HK$0.38) | (HK$0.51) | (HK$0.94) | (HK$0.97) |
| Diluted EPS | (HK$0.29) | (HK$0.38) | (HK$0.51) | (HK$0.94) | (HK$0.97) |
| Revenue Per Share | HK$1.02 | HK$0.17 | HK$0.15 | HK$0.11 | HK$0.26 |
| Shares | |||||
| Basic Shares Outstanding | 628.7M | 626.4M | 620.4M | 615.4M | 617.8M |
| Diluted Shares Outstanding | 641.9M | 626.4M | 620.4M | 615.4M | 617.8M |
| Profitability Metrics | |||||
| EBITDA | (94.2M) | (221.2M) | (348.8M) | (550.3M) | (866.1M) |
| D&A | 34.5M | 17.7M | 15.9M | 30.0M | 12.9M |
| EBIT | (128.7M) | (238.9M) | (364.7M) | (580.3M) | (878.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026